46 results on '"Camanni F"'
Search Results
2. Incidence and prevalence rate estimation of GH treatment exposure in Piedmont pediatric population in the years 2002–2004: Data from the GH Registry
3. Diagnosis of adult growth hormone deficiency: Still a matter of debate
4. Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease
5. Prolonged treatment with glycerophosphocholine, an acetylcholine precursor, does not disclose the potentiating effect of cholinesterase inhibitors on GHRH-induced somatotroph secretion in anorexia nervosa
6. Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly
7. Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1–24) independently of the duration of the disease
8. Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans
9. Normal IGF-I and enhanced IGFBP-3 response to very low rhGH dose in patients with dilated cardiomyopathy
10. Usefulness of IGF-I assay for the diagnosis of GH deficiency in adults
11. Effects of 3-month nifedipine treatment on endocrine-metabolic parameters in patients with abdominal obesity and mild hypertension
12. Reduction of the somatotrope responsiveness to GHRH and Hexarelin but not to arginine plus GHRH in hyperprolactinemic patients
13. Comparison among the effects of arginine, a nitric oxide precursor, isosorbide dinitrate and molsidomine, two nitric oxide donors, on hormonal secretions and blood pressure in man
14. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man
15. Effects of cholinergic blockade by pirenzepine on insulin and glucose response to oral and intravenous glucose and to arginine load in obesity
16. Galanin positively modulates prolactin secretion in normal women
17. Effect of bromocriptine on insulin, growth hormone and prolactin responses to arginine in obesity
18. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man
19. Interaction of salbutamol and galanin on both basal and growth hormone releasing hormone-stimulated growth hormone secretion in humans
20. Glucagon stimulates GH secretion after intramuscular but not intravenous administration. Evidence against the assumption that glucagon per se has a GH-releasing activity
21. Diagnosis of growth hormone deficiency
22. Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration
23. Hormonal and radiological effects of megavoltage radiotherapy in patients with growth hormone-secreting pituitary adenoma
24. Therapeutical doses of salbutamol inhibit the somatotropic responsiveness to growth hormone-releasing hormone in asthmatic children
25. A neuroendocrinological approach to evidence an impairment of central cholinergic function in aging
26. Involvement of Brain Catecholamines and Acetylcholine in Growth Hormone Deficiency States: Pathophysiological, Diagnostic and Therapeutic Implications
27. Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans
28. A new test for the diagnosis of growth hormone deficiency due to primary pituitary impairment: combined administration of pyridostigmine and growth hormone-releasing hormone
29. This letter was forwarded to Drs. E.Ghigo, E. Bartolotta, E. Imperiale, J. Bellone, G. Cardinale, G. Aimaretti, M.R. Valetto, V. Cherubini, M. Maccario, D. Cocchi and F. Camanni whose reply follows
30. Effect of the somatostatin analog D-Trp8, D-Cys14 on glucose, insulin, pancreatic glucagon and growth hormone plasma levels in acromegalics and mild diabetics
31. Inhibition of thyrotropin and prolactin secretion by dopamine in man
32. Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia
33. Hyperprolactinemia: neuroendocrine and diagnostic aspects
34. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone
35. The hypophosphatemia’and hyperkalemic effect of arginine in man
36. Initial treatment of thyrotoxic Graves’ disease with methimazole: a randomized trial comparing different dosages
37. Effects of a new long-acting form of bromocriptine on tumorous hyperprolactinemia
38. Pituitary apoplexy in acromegaly after pituitary computed tomography: spontaneous or induced?
39. Estrogenic treatment does not modify the TSH and PRL responses to domperidone and TRH in patients with tumoral hyperprolactinemia
40. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia
41. Acute administration of pyridostigmine and clonidine has an additive stimulatory effect on GH release in normal children
42. This letter was forwarded to Drs. E.E Müller, F. Camanni and A.R. Genazzani whose reply follows
43. Neurotransmitter control of growth hormone, thyrotropin and prolactin secretion
44. Nomifensine-induced pregnancy in a hyperprolactinemic woman
45. Nomifensine in hyperprolactinemic states
46. Plasma potassium and adrenergic system
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.